Personalis (NASDAQ:PSNL) Stock Price Down 3.5% - Should You Sell?

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) dropped 3.5% during mid-day trading on Thursday . The stock traded as low as $7.28 and last traded at $7.25. Approximately 1,030,780 shares traded hands during trading, a decline of 10% from the average daily volume of 1,139,860 shares. The stock had previously closed at $7.51.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. HC Wainwright upped their target price on Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $7.00 price target on shares of Personalis in a report on Thursday, April 10th. Guggenheim initiated coverage on shares of Personalis in a research note on Thursday, May 15th. They set a "buy" rating and a $6.00 price objective on the stock. Finally, Craig Hallum assumed coverage on shares of Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $7.67.

Personalis Stock Performance

The firm has a market capitalization of $667.26 million, a P/E ratio of -5.86 and a beta of 1.95. The stock has a fifty day moving average price of $5.36 and a two-hundred day moving average price of $4.84.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to the consensus estimate of $17.41 million. Personalis had a negative net margin of 98.10% and a negative return on equity of 48.78%. As a group, research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently bought and sold shares of PSNL. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Personalis during the fourth quarter valued at approximately $28,000. JPMorgan Chase & Co. boosted its position in Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after purchasing an additional 5,654 shares during the period. Focus Partners Wealth bought a new position in Personalis during the 1st quarter worth $47,000. Alpine Global Management LLC acquired a new stake in Personalis in the fourth quarter worth $60,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Personalis by 18.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock worth $62,000 after buying an additional 2,724 shares during the period. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.